Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5742885 | 1.00 | MEN1 (0.43) | MEN1KMT2AALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL2054368 | 1.00 | MEN1 (0.43) | MEN1KMT2AALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL20711832 | 1.00 | MEN1 (0.43) | MEN1KMT2AALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL5742883 | 1.00 | MEN1 (0.43) | MEN1KMT2AALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL29550748 | 0.96 | MEN1 (0.41) | MEN1KMT2AALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL5940491 | 0.96 | MEN1 (0.41) | MEN1KMT2AALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL5940482 | 0.96 | MEN1 (0.41) | MEN1KMT2AALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL29550782 | 0.96 | MEN1 (0.41) | MEN1KMT2AALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL26547622 | 0.93 | MEN1 (0.42) | MEN1KMT2AALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL25706923 | 0.92 | MEN1 (0.38) | MEN1KMT2AALDH1A1HSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115109036-B | Quinazoline compound, composition and application thereof | 北京赛特明强医药科技有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-116157388-A | Carbocyclic amide derivative and application thereof in medicine | 四川海思科制药有限公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-111032646-B | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | 施万生物制药研发IP有限责任公司 | 2023-01-03 | — | — | CN | disclosed |
| CN-115109036-A | Quinazoline compound, composition and application thereof | 北京赛特明强医药科技有限公司 | 2022-09-27 | — | — | CN | disclosed |
| WO-2022194265-A1 | QUINAZOLINE-BASED COMPOUND, COMPOSITION, AND APPLICATION OF QUINAZOLINE-BASED COMPOUND | 北京赛特明强医药科技有限公司 | 2022-09-22 | — | — | WO | disclosed |
| US-20210340105-A1 | AMINOPYRIDINE COMPOUNDS AND METHODS FOR THE PREPARATION AND USE THEREOF | Cortexyme, Inc. (US) | 2021-11-04 | — | — | US | disclosed |
| US-11059786-B2 | Aminopyridine compounds and methods for the preparation and use thereof | Cortexyme, Inc. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20200148642-A1 | AMINOPYRIDINE COMPOUNDS AND METHODS FOR THE PREPARATION AND USE THEREOF | Cortexyme, Inc. (US) | 2020-05-14 | — | — | US | disclosed |
| CN-111032646-A | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | 施万生物制药研发IP有限责任公司 | 2020-04-17 | — | — | CN | disclosed |
| CN-106008471-B | A kind of synthetic method of quinazoline compounds | 江苏医诺万细胞诊疗有限公司 | 2019-09-03 | — | — | CN | disclosed |
| US-5476950-A | Aminopyrrolidine compound | DAIICHI SEIYAKU CO., LTD. (JP) | 1995-12-19 | — | — | US | disclosed |
| US-5416222-A | Chemical intermediates to prepare pyridinocarboxylic acid derivatives with high antimicrobial activity and excellent pharmacokinetics | DAIICHI SEIYAKU CO., LTD. (JP) | 1995-05-16 | — | — | US | disclosed |
| EP-0210883-B1 | Derivatives of penem | DAIICHI SEIYAKU CO (JP) | 1995-02-01 | — | — | EP | disclosed |
| US-5380874-A | Pyrrolidine carbamates | DAIICHI SEIYAKU CO., LTD. (JP) | 1995-01-10 | — | — | US | disclosed |
| EP-0207420-B1 | PYRIDONECARBOXYLIC ACID DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1992-05-06 | — | — | EP | disclosed |
| US-5098912-A | Bactericides for grampositive bacteria | DAIICHI SEIYAKU CO., LTD. (JP) | 1992-03-24 | — | — | US | disclosed |
| US-5079357-A | Bactericides | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1992-01-07 | — | — | US | disclosed |
| US-4962202-A | PENICILLIN INTERMEDIATES | DAIICHI SEIYAKU CO., LTD. (JP) | 1990-10-09 | — | — | US | disclosed |
| EP-0210883-A2 | Derivatives of penem | DAIICHI SEIYAKU CO., LTD. (JP) | 1987-02-04 | — | — | EP | disclosed |
| EP-0207420-A2 | Pyridonecarboxylic acid derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1987-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200148642-A1 | AMINOPYRIDINE COMPOUNDS AND METHODS FOR THE PREPARATION AND USE THEREOF | ENPEP, DNPEP, ANPEP | MEN1 2591/4885KMT2A 1776/4885ALDH1A1 2722/4885 |
| US-11059786-B2 | Aminopyridine compounds and methods for the preparation and use thereof | ENPEP, DNPEP, ANPEP | MEN1 2591/4885KMT2A 1776/4885ALDH1A1 2722/4885 |
| US-20210340105-A1 | AMINOPYRIDINE COMPOUNDS AND METHODS FOR THE PREPARATION AND USE THEREOF | ENPEP, DNPEP, ANPEP | MEN1 2591/4885KMT2A 1776/4885ALDH1A1 2722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.